Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL

Urology

Volumn 56, Issue 6, 2000, Pages 1000-1006

  Babaian, R Joseph ^a   Fritsche, Herbert ^a   Ayala, Alberto ^a   Bhadkamkar, Vijaya ^a   Johnston, Dennis A ^a   Naccarato, William ^b   Zhang, Zhen ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b SIEMENS CORPORATE RESEARCH   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CREATINE KINASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ALGORITHM; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER DIAGNOSIS; CANCER INCIDENCE; COMPARATIVE STUDY; CONTROLLED STUDY; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER;

ACID PHOSPHATASE; ADULT; AGE FACTORS; AGED; ALGORITHMS; BIOPSY; CREATINE KINASE; HUMANS; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0033669367     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00830-X     Document Type: Article

References (23)

1. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: Relationship to gland volume and age
2. Cost-effective prostate cancer detection: Reduction of low-yield biopsies
3. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/ml and benign prostate examination: Enhancement of specificity with free PSA measurements
4. Prostate cancer detection at low prostate specific antigen
5. Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome
6. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years
7. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: An alternative model
8. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy
9. Effectiveness of ProstAsure® in detecting prostate cancer (PCa) and benign prostatic hyperplasia (BPH) in men age 50 and older
10. A neural network (ProstAsure(TM)) with sensitivity and specificity of 75% in detecting prostate cancer in men with a PSA < 4.0 ng/ml
11. Evaluation of ProstAsure index in the detection of prostate cancer: A preliminary report
12. Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data
13. The national survey of prostate cancer in the United States by the American College of Surgeons
14. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen
15. Characteristics of prostate cancers detected in a multimodality early detection program
16. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
17. Role of PSA and its indices in determining the need for repeat prostate biopsies
18. Prostate-specific antigen levels in 1695 men without evidence of prostate cancer: Findings of the American Cancer Society National Prostate Cancer Detection Project
19. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer
20. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
21. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
22. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer